SCHEMBL23924491

SCHEMBL23924491

CCOC(C)C(n1cnc2cnc3ccccc3c21)C(C)(C)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.37
TSHR P16473 1/20 0.35
TLR7 Q9NYK1 6/20 0.34
MPO P05164 1/20 0.34
NUDT1 P36639 1/20 0.32
TLR8 Q9NR97 1/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
MALT1 Q9UDY8 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
RECQL P46063 1/20 0.31
MAPK10 P53779 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
MYC P01106 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21995070 1.00 USP5 (0.37) USP5TSHRTLR7MPONUDT1
SCHEMBL23925018 0.83 USP5 (0.41) USP5TSHRTLR7NUDT1RAB9A
SCHEMBL21995438 0.83 USP5 (0.41) USP5TSHRTLR7NUDT1RAB9A
SCHEMBL21995161 0.83 USP5 (0.36) USP5TSHRTLR7
SCHEMBL23924569 0.83 USP5 (0.36) USP5TSHRTLR7
SCHEMBL23951456 0.81 TLR7 (0.54) TLR7NUDT1TLR8
SCHEMBL22043263 0.81 TLR7 (0.54) TLR7NUDT1TLR8
SCHEMBL21994915 0.81 TLR7 (0.54) TLR7NUDT1TLR8
Hydrochloric Acid SCHEMBL23924563 0.80 TLR7 (0.53) TLR7NUDT1TLR8
Hydrochloric Acid SCHEMBL23924562 0.80 TLR7 (0.53) TLR7NUDT1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2026-02-03 US disclosed
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-09-12 US disclosed
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-07-02 US disclosed
EP-3887369-B1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-08 EP disclosed
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-21 US disclosed
CN-113166143-A N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IRF3, IFNAR1, IFNG USP5 3940/4885TSHR 1299/4885TLR7 51/4885
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods IFNG, IFNAR1, IRF3 USP5 3632/4885TSHR 3075/4885TLR7 20/4885
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 USP5 3406/4885TSHR 2977/4885TLR7 17/4885
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, IRF3 USP5 3406/4885TSHR 2977/4885TLR7 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.